Yawno Tamara, Miller Suzie L, Bennet Laura, Wong Flora, Hirst Jonathan J, Fahey Michael, Walker David W
Ritchie Centre, Hudson Institute of Medical ResearchClayton, VIC, Australia.
Department of Obstetrics and Gynaecology, Monash UniversityClayton, VIC, Australia.
Front Cell Neurosci. 2017 Aug 22;11:246. doi: 10.3389/fncel.2017.00246. eCollection 2017.
Neonatal seizures are amongst the most common neurologic conditions managed by a neonatal care service. Seizures can exacerbate existing brain injury, induce "de novo" injury, and are associated with neurodevelopmental disabilities in post-neonatal life. In this mini-review, we present evidence in support of the use of ganaxolone, a GABA agonist neurosteroid, as a novel neonatal therapy. We discuss evidence that ganaxolone can provide both seizure control and neuroprotection with a high safety profile when administered early following birth-related hypoxia, and show evidence that it is likely to prevent or reduce the incidence of the enduring disabilities associated with preterm birth, cerebral palsy, and epilepsy. We suggest that ganaxolone is an ideal anti-seizure treatment because it can be safely used prospectively, with minimal or no adverse effects on the neonatal brain.
新生儿惊厥是新生儿护理服务中最常见的神经系统疾病之一。惊厥会加重现有的脑损伤，引发“新生”损伤，并与新生儿期后的神经发育障碍相关。在这篇小型综述中，我们提供证据支持使用甘氨酰环素，一种GABA激动剂神经甾体，作为一种新型的新生儿治疗方法。我们讨论了证据表明，在出生相关缺氧后早期给药时，甘氨酰环素可以提供癫痫控制和神经保护，且安全性高，并表明它有可能预防或降低与早产、脑瘫和癫痫相关的持久性残疾的发生率。我们认为甘氨酰环素是一种理想的抗惊厥治疗药物，因为它可以前瞻性地安全使用，对新生儿大脑的不良影响极小或没有。
